P054 The evaluation of transcranial magnetic stimulation rTMS in corticobasal degeneration (CBD): PET, QEEG and neuropsychological correlates

Abstract

Background CBD is a neurodegenerative disorder characterized by asymmetric motor parkinsonism symptomatology and impairment in language, personality and affective functions that are related to frontoparietal atrophy. To date, there is still no effective treatment for CBD. In this respect, TMS may be a novel therapeutic candidate for CBS. Considering all of this evidence, we aimed to evaluate the pre and post-treatment electrophysiological, neurometabolic and neuropsychometric correlates of TMS application in four CBS patients. Methods We have evaluated the pre and post treatment EEG, FDG-PET and detailed clinical behavioral and neuropsychometric test correlates of TMS in four CBD patients who were admitted to our dementia outpatient at the University of Medipol-Istanbul. The following detailed neuropsychometric test procedures were applied to patients; Digit Span (Forward/Back) Test, Verbal Fluency Test, Lexical Fluency Test, Clock Drawing Test, Similarities and Comprehension test, Verbal Learning Test (SBSTTA-Oktem), Wechsler Memory Scale (WMS-Logical Memory Test), Benton Face Recognition Test (BFR), Line Orientation Identification Test (BLOT), Neuropsychiatric Inventory (NPI), Geriatric Depression Scale (GDS), Frontal Behavioral Inventory Test (FBI), Standardized Mini Mental State Examination (MMSE) and Clinical Dementia Rating-Scale (CDR). Results & conclusion We have found that increased pretreatment theta activity was significantly decreased after the TMS treatment in frontal, central and parietal regions that was associated with the normalized glucose metabolism and neurobehavioral test scores after the TMS treatment.